Pharmacy Automation Market worth US$10.00 billion by 2030 with 7.1% CAGR
"The United Nations Population Fund (UNFPA) predicts people aged 65 and older will grow from our present 10.3% worldwide population in 2024 to 20.7% by 2074, leading to a surge in the number of elderly patients requiring long-term medication management. Based on a Harvard University housing study 2023, almost 70% of elderly people (over age 65) are likely to need long-term assistance in their lifespan"
Browse 387 market data Tables and 50 Figures spread through 388 Pages and in-depth TOC on "Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counter, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient, Retail, ASC), Facility (Large, Mid) - Global Forecast to 2030
The global Pharmacy Automation Market, valued at US$6.23 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching US$6.65 billion in 2024 and an impressive US$10.00 billion by 2030. The growth of the market is mainly fueled by the increasing incidence of chronic diseases, enhancing the need for effective and precise management of drugs. Moreover, the requirement of efficient pharmacy operations to boost the efficiency of the workflow and cut down medication mistakes is accelerating the usage of automation. Furthermore, government initiatives and policies promoting digital health and automation are propelling market growth.
Furthermore, major industry players are increasingly focusing on AI-driven solutions, cloud-based pharmacy management systems, and strategic partnerships to enhance operational efficiency. The expansion of e-pharmacies, along with the growing integration of IoT in healthcare, is expected to create new growth opportunities. As technological advancements continue to transform the pharmacy sector, automation is becoming an essential solution for improving medication safety, reducing costs, and optimizing overall pharmaceutical operations.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890
Browse in-depth TOC on " Pharmacy Automation Market"
200 - Tables
50 - Figures
300 - Pages
By Based on product type, the pharmacy automation market has been segmented into automated medication dispensing and storage systems, automated packaging and labeling systems, automated tabletop counters, automated medication compounding systems, pharmacy management software (PMS/PIMS/PIS), and other pharmacy automation systems (pharmacy kiosks, pneumatic tubes, tablet splitters, and others). In 2023, the automated medication dispensing and storage systems segment is estimated to hold the largest share of the market for pharmacy automation. Some of the key growth factors for the segment are increasing need for reducing medication errors. Medication dispensing errors, such as incorrect dosage, wrong medications, and dispensing delays, contribute to adverse drug events (ADEs), impacting patient health outcomes. For instance, according to the World Health Organization (WHO) 2022, medication errors are estimated to cost approximately USD 42 billion annually. Further, in hospital settings, medication error rates range from 0.3% to 9.1% during prescribing and 1.6% to 2.1% at the dispensing stage. Automation minimizes human errors by ensuring precise dispensing and secure storage. Technologies such as robotic dispensers help prevent contamination and ensure correct medication dispensing.
By End user, the retail pharmacies segment is expected to grow at the fastest CAGR over the forecast period. This rapid expansion is fueled by the rising demand for streamlined pharmacy operations, growing prescription volumes, and the need for faster, more accurate medication dispensing. The increasing shift toward digital health solutions, coupled with advancements in robotic dispensing, AI-driven inventory management, and cloud-based pharmacy systems, is transforming how retail pharmacies operate. Additionally, the push for improved customer convenience, including same-day prescription deliveries and automated refill systems, is accelerating the adoption of pharmacy automation technologies. Major retailers such as Walmart and Amazon are intensifying competition in the US prescription medication market by introducing same-day delivery services. For instance, in January 2025, Walmart announced the nationwide expansion of its same-day pharmacy delivery service in 49 states by the end of January 2025. This move intensifies competition with Amazon's expanding prescription services and traditional retail pharmacies such as CVS and Walgreens, which are struggling with store closures. The service aims to provide faster, more convenient prescription access for customers, particularly busy families, seniors, and chronic disease patients.
By geography, the pharmacy automation market is segmented into five major regions: North America, Asia Pacific, Europe, Middle East & Africa, and Latin America. In 2023, North America accounted for the highest share in pharmacy automation market driven by its well-established healthcare infrastructure, high adoption of advanced technologies, and stringent regulatory requirements for medication safety. The region's dominance is fueled by the increasing demand for automated medication dispensing, packaging, and inventory management solutions in both hospital and retail pharmacy settings. Regulatory bodies such as the FDA, DEA, and HIPAA have set strict guidelines for medication management, pushing pharmacies and healthcare institutions to integrate automation to ensure compliance and reduce medication errors. Additionally, the presence of leading market players, including Omnicell, BD, Swisslog Healthcare, and Baxter International Inc, accelerated innovation and widespread adoption of automation technologies. The rise of retail pharmacy automation, with major chains such as Walmart, CVS, Walgreens, and Amazon Pharmacy investing in AI-powered prescription fulfillment and same-day delivery services, further strengthened North America's leadership in the market.
The pharmacy automation market is consolidated at the top with a large number of leading market players based in developed countries. The key players operating in this market are Becton, Dickinson and Company (US), Omnicell, Inc. (US), KUKA AG (Swisslog Healthcare) (Germany), Baxter International Inc. (US), Capsa Healthcare (US), Oracle (US), Yuyama Co., Ltd. (Japan), ARxIUM Inc. (US), Mckesson Corporation (US), RxSafe, LLC (US), ScriptPro LLC (US), Pearson Medical Technologies, LLC (US), Deenova S.R.L (Germany), Medical Packaging Inc., LLC (US), Tension Corporation (US), Noritsu Pharmacy Automation (US), Euclid Medical Products (US), TouchPoint Medical Solutions (US), Innovation Associates (US), and JFCRX (US). Because of the high level of competition in the market, major market players are becoming more inclined to grow their presence in the high-growth markets by employing both organic and inorganic growth initiatives like product launches, and acquisitions.
Becton, Dickinson and Company (BD) (US):
BD is a worldwide manufacturer of high-quality pharmacy automation solutions that reinforce its market position via organic growth strategies like investments in research & development activities. BD spent USD 1.33 billion and USD 1.09 billion in R&D in 2021 and 2020, respectively. Further, the strong geographical presence, extensive distribution network, and brand image of the company has made itself a market leader in the worldwide arena.
Omnicell, Inc. (US):
Omnicell is among the most dominant companies in the pharmacy automation sector. The firm has a very wide line of pharmacy automation systems with high brand value that has enabled it to establish a competitive advantage in the pharmacy automation sector and a leading global position. The firm has a focus on inorganic expansion through acquiring firms. Omnicell bought MarkeTouch Media, LLC (US) to further its presence in the retail pharmacy market. It also bought ReCept Holdings, Inc. (US) to further its portfolio of advanced services.
KUKA AG (Swisslog Healthcare) (Germany):
KUKA AG (Swisslog Healthcare) (Germany): KUKA provides an extensive array of pharmacy automation solutions under its Swisslog Healthcare business segment. Swisslog Healthcare emphasizes growing its business by expanding product development and geographical presence. Swisslog Healthcare expanded its business through the development of the UniPick 2 outpatient drug dispensing automation solution in hospital pharmacies (outpatient solutions) in the fast-expanding Chinese market. New products established and improvements have given Swisslog a competitive edge over its peers in the market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
Dr. Konstantinos Zarkadas Launches National Scholarship to Empower Aspiring Medical Leaders
Transformative Initiative Offers Financial Support to Future Physicians Committed to Service and Excellence GLEN COVE, NEW YORK - June 20, 2025 - In a bold step toward fostering the next generation of compassionate, driven medical professionals, Dr. Konstantinos Zarkadas, a respected leader in the healthcare sector, proudly announces the inauguration of the Dr. Konstantinos Zarkadas Scholarship for Future Doctors. This prestigious national scholarship aims to identify, support, and inspire undergraduate students who exhibit exceptional academic ability, a deep commitment to medicine, and a dedication to improving community health outcomes. The scholarship will award a one-time $1,000 grant to a single undergraduate student who meets the rigorous eligibility criteria. Applications are now open, with the deadline set for November 15, 2025. The recipient will be publicly announced on December 15, 2025. 'The future of medicine depends on individuals who lead with both intellect and empathy,' said Dr. Konstantinos Zarkadas. 'Through this scholarship, I hope to ease the financial burdens faced by aspiring doctors while encouraging them to embrace the calling of medical service with integrity, leadership, and vision. This is not just an award—it is an investment in the future of healthcare.' Dr. Zarkadas brings over two decades of experience in clinical practice and medical leadership. His academic journey, which includes a degree in Psychology from Hunter College, advanced medical training in the Dominican Republic, and a Master of Health Administration from Columbia University, has shaped his unique perspective on holistic and inclusive healthcare delivery. Currently serving as Chief Medical Officer at Arch Sleep Apnea Solutions and leading multiple medical practices, Dr. Konstantinos Zarkadas is deeply committed to transforming community health through culturally competent and patient-centered care. The Dr. Konstantinos Zarkadas Scholarship for Future Doctors has been thoughtfully designed to recognize students who combine academic excellence with a strong sense of social responsibility. Eligible applicants must meet the following criteria: Current Undergraduate Enrollment: Students must be enrolled at an accredited U.S. college or university. Pre-Medical Focus: Candidates must be pursuing a pre-med track or a closely related field, with clear intent to enter medical school. Academic Performance: A minimum cumulative GPA of 3.5 is required. Residency: Open to U.S. citizens and permanent residents. Leadership and Service: Applicants should demonstrate leadership potential and a history of meaningful community involvement. Commitment to Medicine: Candidates must clearly articulate their passion for medicine and dedication to a career in healthcare. Fluent in English, Greek, and Spanish, Dr. Konstantinos Zarkadas has long been an advocate for health equity and multicultural competence in medical practice. His past collaborations with organizations like Somos Community Care ACO and his leadership role in medical education at The New Parkway Hospital underscore his unwavering mission to mentor and empower the next wave of healthcare providers. Unlike many geographically limited programs, this scholarship is open to qualified students nationwide. Applicants must submit an original essay reflecting on their motivation to pursue medicine, their experiences in community service, and their vision for contributing meaningfully to the healthcare field. This narrative component is central to the selection process, allowing students to highlight not only their achievements but their potential for lasting impact. Comprehensive application guidelines and submission instructions can be found at: By championing students who exemplify both academic rigor and humanitarian values, the Dr. Konstantinos Zarkadas Scholarship for Future Doctors seeks to elevate the standards of tomorrow's medical profession. This initiative affirms Dr. Zarkadas's enduring belief that investing in education and ethical leadership is the surest path to a stronger, more inclusive American healthcare system. Media Contact Company Name: Dr. Konstantinos Zarkadas Scholarship Contact Person: Dr. Konstantinos Zarkadas Email: Send Email City: GLEN COVE State: NEW YORK Country: United States Website:
Globe and Mail
21 minutes ago
- Globe and Mail
Don't Overlook Jabil (JBL) Stock After Topping Its Q3 Expectations
Jabil Inc. JBL was a notable standout in a relatively quiet earnings lineup this week, as investors eyed ongoing conflicts in the Middle East that could potentially impact markets. That said, Jabil is one of the largest global suppliers of electronics manufacturing services and is worthy of investors' attention after posting strong results for its fiscal third quarter on Tuesday. Trading near 52-week highs of over $200 a share, here's a look at why Jabil stock may be poised for more upside. Jabil Customer Base Overview Serving a wide range of major global companies across various industries, two of Jabil's most prominent customers include Apple AAPL and Amazon AMZN. As two of its largest clients, Apple relies on Jabil's manufacturing components for iPhones, among other devices, with Amazon relying on Jabil's computing and hardware services for AWS. While Apple and Amazon have accounted for significant portions of Jabil's revenue, the company has made significant efforts to diversify its customer base, with other noteworthy and diverse clients being healthcare giant Johnson & Johnson JNJ and communication networks leader Ericsson ERIC. Jabil's Strong Q3 Results Briefly reviewing Jabil's strong quarterly results, Q3 sales spiked 15% year over year to $7.82 billion and topped estimates of $7.08 billion by 10%. More impressive, Q3 EPS of $2.55 soared 35% from $1.89 in the comparative quarter and beat earnings expectations of $2.33 per share by 9%. Continuing its compelling and consistent operational performance, Jabil has now surpassed the Zacks EPS Consensus for 21 consecutive quarters with an average earnings surprise of 6.68% over the last four quarters. Jabil's Guidance & Outlook Offering guidance for its fiscal fourth quarter, Jabil expects Q4 sales in the range of $7.1 billion-$7.8 billion, with the current Zacks Consensus at $7.55 billion or 8% growth. Jabil expects Q4 EPS at $2.64-$3.04, with Zacks projections currently at $2.75 or 19% growth. Correlating with its diverse customer base and strategic alignment with secular trends such as AI, Jabil expects to see continued revenue expansion, margin enhancement, and robust free cash flow generation in the coming years. JBL Performance & Valuation Year to date, Jabil stock is up over +40% and has blown away the performance of the broader indexes, which have been virtually flat. More intriguing, JBL is sitting on gains of more than +200% in the last three years to impressively outpace the stock performances of its top big tech customers in Amazon and Apple and the benchmark S&P 500 and Nasdaq's returns of +60% and +80%, respectively. Image Source: Zacks Investment Research Despite vastly outperforming the broader market, JBL still trades at a slight discount to the benchmark at 22.9X forward earnings. This is also a noticeable discount to the high P/E premiums that many top-performing tech stocks can command. Conclusion & Final Thoughts Jabil stock currently sports a Zacks Rank #2 (Buy) as earnings estimates have started to trend higher following its strong Q3 results for fiscal 2025 and FY26. Also suggesting JBL is worthy of investors' consideration is that Jabil is on track to generate over $1.2 billion in free cash flow this year and has a healthy balance sheet with debt to core EBITDA levels of approximately 1.4X. Furthermore, Jabil is on track to complete a $1 billion share repurchase plan, reflecting management's confidence that its strong operational performance will continue. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Jabil, Inc. (JBL): Free Stock Analysis Report Inc. (AMZN): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Ericsson (ERIC): Free Stock Analysis Report
Globe and Mail
27 minutes ago
- Globe and Mail
National Healthcare Properties Announces Preferred Stock Dividends
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) ('NHP') announced today that it declared quarterly dividends on its outstanding preferred stock. Specifically, NHP declared a dividend of $0.4609375 per share on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock payable on July 15, 2025 to holders of record at the close of business on July 3, 2025. In addition, NHP declared a dividend of $0.4453125 per share on its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock payable on July 15, 2025 to holders of record at the close of business on July 3, 2025. About National Healthcare Properties, Inc. National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) is a publicly registered real estate investment trust focused on acquiring a diversified portfolio of healthcare real estate, with an emphasis on seniors housing and outpatient medical facilities, located in the United States. Additional information about NHP can be found on its website at Important Notice The statements in this press release that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause actual results or events to be materially different. The words 'anticipates,' 'believes,' 'expects,' 'estimates,' 'projects,' 'plans,' 'intends,' 'may,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and other factors, many of which are outside of NHP's control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the risks associated with realization of the anticipated benefits of NHP's internalization of its property management and advisory functions; and that NHP's ongoing or potential future transactions are subject to market conditions and capital availability and may not be identified or completed on favorable terms or at all. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause NHP's actual results to differ materially from those presented in its forward-looking statements are set forth in the 'Risk Factors' section in NHP's Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in NHP's subsequent reports. Further, forward-looking statements speak only as of the date they are made, and NHP undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law. Contacts
